Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,876 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03994627 | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 11 | Dec 16, 2024 | clinicaltrials |
| NCT03817515 | Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation | approved for marketing | — | — | Aadi Bioscience, Inc.INDUSTRY | 0 | Mar 16, 2022 |
| clinicaltrials |
| NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | approved for marketing | — | — | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | May 29, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Dec 16, 2024source: clinicaltrials